JP2023089012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023089012A5 JP2023089012A5 JP2023048083A JP2023048083A JP2023089012A5 JP 2023089012 A5 JP2023089012 A5 JP 2023089012A5 JP 2023048083 A JP2023048083 A JP 2023048083A JP 2023048083 A JP2023048083 A JP 2023048083A JP 2023089012 A5 JP2023089012 A5 JP 2023089012A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- treatment
- salt
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 7
- -1 besylates Chemical class 0.000 claims 6
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100034111 Activin receptor type-1 Human genes 0.000 claims 4
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 claims 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 208000034970 Heterotopic Ossification Diseases 0.000 claims 3
- 239000002253 acid Chemical class 0.000 claims 3
- 230000007941 heterotopic ossification Effects 0.000 claims 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 229930195712 glutamate Natural products 0.000 claims 2
- 229940049906 glutamate Drugs 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 235000005152 nicotinamide Nutrition 0.000 claims 2
- 239000011570 nicotinamide Substances 0.000 claims 2
- 229960003966 nicotinamide Drugs 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 claims 1
- DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical class C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- 159000000021 acetate salts Chemical class 0.000 claims 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 1
- 150000008064 anhydrides Chemical group 0.000 claims 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 150000003842 bromide salts Chemical class 0.000 claims 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 150000001805 chlorine compounds Chemical class 0.000 claims 1
- 125000005534 decanoate group Chemical class 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims 1
- 229940043264 dodecyl sulfate Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 claims 1
- 229940050410 gluconate Drugs 0.000 claims 1
- 229940097042 glucuronate Drugs 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 1
- 229940001447 lactate Drugs 0.000 claims 1
- 229940099584 lactobionate Drugs 0.000 claims 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- XENHFSZRMFXQBS-UHFFFAOYSA-N phosphoric acid;pyridine-3-carboxamide Chemical compound OP(O)(O)=O.NC(=O)C1=CC=CN=C1 XENHFSZRMFXQBS-UHFFFAOYSA-N 0.000 claims 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical class OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 claims 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
- 125000005490 tosylate group Chemical group 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 150000004684 trihydrates Chemical class 0.000 claims 1
- 229950000339 xinafoate Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193634A JP2025032086A (ja) | 2016-07-20 | 2024-11-05 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364620P | 2016-07-20 | 2016-07-20 | |
| US62/364,620 | 2016-07-20 | ||
| JP2019502675A JP7030776B2 (ja) | 2016-07-20 | 2017-07-18 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| PCT/CN2017/093385 WO2018014829A1 (en) | 2016-07-20 | 2017-07-18 | Aminopyridine derivatives and their use as selective alk-2 inhibitors |
| JP2022025894A JP7253086B2 (ja) | 2016-07-20 | 2022-02-22 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025894A Division JP7253086B2 (ja) | 2016-07-20 | 2022-02-22 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193634A Division JP2025032086A (ja) | 2016-07-20 | 2024-11-05 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023089012A JP2023089012A (ja) | 2023-06-27 |
| JP2023089012A5 true JP2023089012A5 (enExample) | 2023-11-24 |
| JP7584553B2 JP7584553B2 (ja) | 2024-11-15 |
Family
ID=60991950
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502675A Active JP7030776B2 (ja) | 2016-07-20 | 2017-07-18 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2022025894A Active JP7253086B2 (ja) | 2016-07-20 | 2022-02-22 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2023048083A Active JP7584553B2 (ja) | 2016-07-20 | 2023-03-24 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2024193634A Pending JP2025032086A (ja) | 2016-07-20 | 2024-11-05 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502675A Active JP7030776B2 (ja) | 2016-07-20 | 2017-07-18 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
| JP2022025894A Active JP7253086B2 (ja) | 2016-07-20 | 2022-02-22 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193634A Pending JP2025032086A (ja) | 2016-07-20 | 2024-11-05 | アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10710980B2 (enExample) |
| EP (3) | EP3487851B1 (enExample) |
| JP (4) | JP7030776B2 (enExample) |
| KR (7) | KR102359707B1 (enExample) |
| CN (2) | CN109641871B (enExample) |
| AR (1) | AR109108A1 (enExample) |
| AU (5) | AU2017298187B2 (enExample) |
| CY (1) | CY1124967T1 (enExample) |
| DK (2) | DK3487851T3 (enExample) |
| EA (2) | EA202190285A1 (enExample) |
| ES (2) | ES2984746T3 (enExample) |
| FI (1) | FI3971177T3 (enExample) |
| HR (2) | HRP20211868T1 (enExample) |
| HU (2) | HUE057328T2 (enExample) |
| LT (2) | LT3971177T (enExample) |
| MX (2) | MX388518B (enExample) |
| PL (2) | PL3971177T3 (enExample) |
| PT (2) | PT3971177T (enExample) |
| RS (2) | RS66041B1 (enExample) |
| RU (1) | RU2747318C2 (enExample) |
| SI (2) | SI3971177T1 (enExample) |
| SM (2) | SMT202100723T1 (enExample) |
| TW (5) | TWI806385B (enExample) |
| UY (1) | UY37331A (enExample) |
| WO (1) | WO2018014829A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3971177T3 (pl) * | 2016-07-20 | 2024-10-28 | Novartis Ag | Pochodne aminopirydyny i ich zastosowanie jako selektywne inhibitory alk-2 |
| CA3160312A1 (en) | 2019-11-22 | 2021-05-27 | Incyte Corporation | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
| CN111170893B (zh) * | 2020-01-19 | 2022-04-26 | 郑州依米花手性药物研究有限公司 | Lefamulin的中间体化合物及其在Lefamulin制备中的应用 |
| MX2022015900A (es) * | 2020-06-16 | 2023-01-24 | Incyte Corp | Inhibidores de alk2 para el tratamiento de la anemia. |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| CN116478145B (zh) * | 2022-04-13 | 2024-02-02 | 杭州邦顺制药有限公司 | Alk2激酶抑制剂 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| ATE234920T1 (de) | 1992-11-17 | 2003-04-15 | Ludwig Inst Cancer Res | Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen |
| TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| US6914058B2 (en) * | 2002-01-18 | 2005-07-05 | Dr. Reddy's Laboratories, Limited | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP4901102B2 (ja) | 2002-05-03 | 2012-03-21 | エクセリクシス， インク． | プロテインキナーゼモジュレーターおよびその使用方法 |
| US7015227B2 (en) | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
| US20040067985A1 (en) | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| SE0203753D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| AU2004230519A1 (en) | 2003-04-11 | 2004-10-28 | Sgx Pharmaceuticals, Inc. | Compound libraries and methods for drug discovery |
| BRPI0511571A (pt) | 2004-05-27 | 2008-01-02 | Pfizer | derivados de aminopiridina como agonistas de dopamina d3 seletivos |
| SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| CA2603959A1 (en) | 2005-04-08 | 2006-10-19 | Eisai R & D Management Co., Ltd. | Therapeutic agent for dyskinesia |
| WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| PE20071241A1 (es) * | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
| CA2649770C (en) | 2006-04-18 | 2017-08-15 | The Trustees Of The University Of Pennsylvania | Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop) |
| EP2069313A2 (en) | 2006-06-29 | 2009-06-17 | Alantos Pharmaceuticals Holdings, Inc. | Metalloprotease inhibitors |
| BRPI0714893A2 (pt) | 2006-09-05 | 2013-05-28 | Medarex Inc | anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo |
| JP2010503383A (ja) | 2006-09-12 | 2010-02-04 | ザ ジェネラル ホスピタル コーポレイション | 細胞シグナリングをモジュレートする化合物を同定するための方法およびこのような化合物を使用する方法 |
| UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
| CA2718403A1 (en) | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| MX2010013876A (es) | 2008-06-20 | 2011-03-04 | Metabolex Inc | Agonistas de arilo grpr119 y sus usos . |
| AU2011292810B2 (en) | 2010-08-20 | 2015-04-30 | Wyeth Llc | Designer osteogenic proteins |
| KR20140014104A (ko) | 2010-12-06 | 2014-02-05 | 피라말 엔터프라이지즈 리미티드 | 치환된 이미다조퀴놀린 유도체 |
| WO2012087938A1 (en) | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
| WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| AU2012259333B2 (en) | 2011-05-23 | 2017-06-08 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
| CA3123737A1 (en) | 2011-09-09 | 2013-03-14 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| CA2886187C (en) * | 2012-09-28 | 2020-04-14 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| US20160115167A1 (en) * | 2013-03-04 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| US10202356B2 (en) * | 2013-03-14 | 2019-02-12 | Tolero Pharmaceuticals, Inc. | JAK2 and ALK2 inhibitors and methods for their use |
| JP6542192B2 (ja) | 2013-03-14 | 2019-07-10 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Ｂｍｐ阻害剤およびその使用方法 |
| SG10201901902WA (en) | 2013-10-21 | 2019-04-29 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
| WO2015152183A1 (ja) | 2014-03-31 | 2015-10-08 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
| CA2973873A1 (en) | 2015-01-20 | 2016-07-28 | Merial, Inc. | Anthelmintic compounds, compositions and method of using thereof |
| CR20180184A (es) | 2015-08-31 | 2018-08-23 | Dong A Socio Holdings Co Ltd | Compuestos heteroarilo y su uso como fármacos terapéuticos |
| US11462835B2 (en) | 2016-07-20 | 2022-10-04 | Qorvo Us, Inc. | Method for tuning an antenna with a DVC |
| PL3971177T3 (pl) * | 2016-07-20 | 2024-10-28 | Novartis Ag | Pochodne aminopirydyny i ich zastosowanie jako selektywne inhibitory alk-2 |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
-
2017
- 2017-07-18 PL PL21202619.9T patent/PL3971177T3/pl unknown
- 2017-07-18 TW TW111103316A patent/TWI806385B/zh active
- 2017-07-18 LT LTEP21202619.9T patent/LT3971177T/lt unknown
- 2017-07-18 KR KR1020217022916A patent/KR102359707B1/ko active Active
- 2017-07-18 RS RS20241041A patent/RS66041B1/sr unknown
- 2017-07-18 ES ES21202619T patent/ES2984746T3/es active Active
- 2017-07-18 KR KR1020247034434A patent/KR20240155367A/ko active Pending
- 2017-07-18 DK DK17830463.0T patent/DK3487851T3/da active
- 2017-07-18 US US16/318,250 patent/US10710980B2/en active Active
- 2017-07-18 RS RS20211582A patent/RS62819B1/sr unknown
- 2017-07-18 HR HRP20211868TT patent/HRP20211868T1/hr unknown
- 2017-07-18 MX MX2019000837A patent/MX388518B/es unknown
- 2017-07-18 PT PT212026199T patent/PT3971177T/pt unknown
- 2017-07-18 SI SI201731538T patent/SI3971177T1/sl unknown
- 2017-07-18 EP EP17830463.0A patent/EP3487851B1/en active Active
- 2017-07-18 TW TW106123900A patent/TWI712598B/zh active
- 2017-07-18 LT LTEPPCT/CN2017/093385T patent/LT3487851T/lt unknown
- 2017-07-18 KR KR1020237024969A patent/KR102667331B1/ko active Active
- 2017-07-18 WO PCT/CN2017/093385 patent/WO2018014829A1/en not_active Ceased
- 2017-07-18 HR HRP20241015TT patent/HRP20241015T1/hr unknown
- 2017-07-18 AU AU2017298187A patent/AU2017298187B2/en active Active
- 2017-07-18 KR KR1020197004529A patent/KR102281550B1/ko active Active
- 2017-07-18 RU RU2019104609A patent/RU2747318C2/ru active
- 2017-07-18 FI FIEP21202619.9T patent/FI3971177T3/fi active
- 2017-07-18 TW TW113124586A patent/TW202509017A/zh unknown
- 2017-07-18 HU HUE17830463A patent/HUE057328T2/hu unknown
- 2017-07-18 KR KR1020247016068A patent/KR102719881B1/ko active Active
- 2017-07-18 DK DK21202619.9T patent/DK3971177T3/da active
- 2017-07-18 TW TW112118991A patent/TWI851226B/zh active
- 2017-07-18 SI SI201731040T patent/SI3487851T1/sl unknown
- 2017-07-18 ES ES17830463T patent/ES2902521T3/es active Active
- 2017-07-18 SM SM20210723T patent/SMT202100723T1/it unknown
- 2017-07-18 KR KR1020227034980A patent/KR102559539B1/ko active Active
- 2017-07-18 PT PT178304630T patent/PT3487851T/pt unknown
- 2017-07-18 PL PL17830463T patent/PL3487851T3/pl unknown
- 2017-07-18 KR KR1020227003660A patent/KR102454129B1/ko active Active
- 2017-07-18 TW TW110101592A patent/TWI755255B/zh active
- 2017-07-18 CN CN201780044640.4A patent/CN109641871B/zh active Active
- 2017-07-18 EP EP21202619.9A patent/EP3971177B1/en active Active
- 2017-07-18 EA EA202190285A patent/EA202190285A1/ru unknown
- 2017-07-18 HU HUE21202619A patent/HUE067992T2/hu unknown
- 2017-07-18 SM SM20240335T patent/SMT202400335T1/it unknown
- 2017-07-18 JP JP2019502675A patent/JP7030776B2/ja active Active
- 2017-07-18 CN CN202111145806.6A patent/CN114014844B/zh active Active
- 2017-07-18 EP EP24183394.6A patent/EP4442317A3/en active Pending
- 2017-07-18 EA EA201990343A patent/EA037520B1/ru unknown
- 2017-07-19 UY UY0001037331A patent/UY37331A/es not_active Application Discontinuation
- 2017-07-20 AR ARP170102033A patent/AR109108A1/es unknown
-
2019
- 2019-01-18 MX MX2021014852A patent/MX2021014852A/es unknown
- 2019-10-10 AU AU2019246857A patent/AU2019246857B2/en active Active
-
2020
- 2020-05-27 US US16/884,666 patent/US10947218B2/en active Active
-
2021
- 2021-02-08 US US17/170,690 patent/US12466808B2/en active Active
- 2021-03-04 AU AU2021201424A patent/AU2021201424C1/en active Active
- 2021-12-29 CY CY20211101137T patent/CY1124967T1/el unknown
-
2022
- 2022-02-22 JP JP2022025894A patent/JP7253086B2/ja active Active
-
2023
- 2023-01-19 AU AU2023200265A patent/AU2023200265B2/en active Active
- 2023-03-24 JP JP2023048083A patent/JP7584553B2/ja active Active
-
2024
- 2024-07-24 AU AU2024205058A patent/AU2024205058A1/en active Pending
- 2024-11-05 JP JP2024193634A patent/JP2025032086A/ja active Pending